Aug 6, 2026 7:00 am EDT Opus Genetics Announces Financial Results for Second Quarter 2026 and Provides Corporate Update
Aug 3, 2026 7:00 am EDT Opus Genetics Completes Patient Enrollment in Registrational Phase 3 Trial of OPGx-LCA5 for LCA5-Associated Inherited Retinal Disease
Jul 9, 2026 7:00 am EDT Opus Genetics Provides BEST1 Program Update with Detailed Timeline for OPGx-BEST1 Results
Jul 6, 2026 7:00 am EDT Opus Genetics Announces FDA Alignment on Phase 3 Registrational Trial Design for OPGx-LCA5 in LCA5-Associated Inherited Retinal Disease
Jun 26, 2026 9:15 am EDT Opus Genetics Added to the Russell 3000®, Russell 2000® and Russell Microcap® Indexes
Jun 16, 2026 4:05 pm EDT Opus Genetics Highlights Five Gene Therapy Programs Targeting Significant Unmet Need in Patients with Inherited Retinal Diseases
Jun 2, 2026 7:00 am EDT Opus Genetics to Host Virtual R&D Science Forum on Tuesday, June 16, 2026 Featuring Multiple Inherited Retinal Disease Experts
May 28, 2026 4:01 pm EDT Opus Genetics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
May 13, 2026 7:00 am EDT Opus Genetics to Present at the RBC Capital Markets 2026 Global Healthcare Conference